Abstract
Malignant melanoma represents one of the most aggressive malignancies but outcome is highly variable with early tumor lesions having an excellent prognosis following resection. We review here the data on identification of genes involved in the progression of melanoma as a result of expression array studies, genomic profiling, and genetic models. We focus on the role of tumor suppressors involved in cell cycle function, DNA repair, and genome maintenance. Highlighted are the roles of loss of p16 in promoting neoplasia in cooperation with deregulated MAPK signaling, and the role of loss of the RASSF1A protein in promoting chromosomal instability. The interactions between point mutation in growth signaling molecules and epigenetic changes in genes involved in DNA repair and cell division are discussed.
Keywords: Melanoma, genetic progression, tumor suppressors, cell cycle, alkylating agents, mitotic spindle, mitotic spindle poisons
Current Genomics
Title: Molecular Markers of Tumor Progression in Melanoma
Volume: 10 Issue: 4
Author(s): Joshua Rother and Dan Jones
Affiliation:
Keywords: Melanoma, genetic progression, tumor suppressors, cell cycle, alkylating agents, mitotic spindle, mitotic spindle poisons
Abstract: Malignant melanoma represents one of the most aggressive malignancies but outcome is highly variable with early tumor lesions having an excellent prognosis following resection. We review here the data on identification of genes involved in the progression of melanoma as a result of expression array studies, genomic profiling, and genetic models. We focus on the role of tumor suppressors involved in cell cycle function, DNA repair, and genome maintenance. Highlighted are the roles of loss of p16 in promoting neoplasia in cooperation with deregulated MAPK signaling, and the role of loss of the RASSF1A protein in promoting chromosomal instability. The interactions between point mutation in growth signaling molecules and epigenetic changes in genes involved in DNA repair and cell division are discussed.
Export Options
About this article
Cite this article as:
Rother Joshua and Jones Dan, Molecular Markers of Tumor Progression in Melanoma, Current Genomics 2009; 10(4) . https://dx.doi.org/10.2174/138920209788488526
DOI https://dx.doi.org/10.2174/138920209788488526 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications
Current Cancer Drug Targets Ultrasound Enhances the Transfection of Plasmid DNA by Non-viral Vectors
Current Pharmaceutical Biotechnology Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Spongiane Diterpenoids
Current Bioactive Compounds Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Regulation of p53 Activity
Current Chemical Biology Obesity and Cancer: Biological Links and Treatment Implications
Current Cancer Drug Targets Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments
Current Clinical Pharmacology Improving DNA Vaccine Performance Through Vector Design
Current Gene Therapy Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review
Drug Delivery Letters Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics